T1	Participants 24 68	adults with established rheumatoid arthritis
T2	Participants 240 275	refractory rheumatoid arthritis (RA
T3	Participants 318 330	714 patients
T4	Participants 1556 1572	patients with RA
T5	Participants 1664 1748	The benefit-to-risk ratio for longterm etanercept treatment remains highly favorable
